ASTRAZENECA PLC |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 12,026 GBX | +5.94% |
|
+10.41% | +13.68% |
| 12:52pm | FTSE 100 hits high on offer for Anglo American | AN |
| 12:31pm | AstraZeneca Q1 Core Earnings, Revenue Increase -- Shares Jump Premarket | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
Pharmaceuticals
Calendar
02:00am
- Q1 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B+
Sell
Buy
Mean consensus
BUY
Number of Analysts
22
Last Close Price
141.1
USD
Average target price
161.4
USD
Spread / Average Target
+14.36%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +13.68% | 219B | |
| +25.61% | 660B | |
| +22.52% | 562B | |
| -5.24% | 358B | |
| +16.49% | 322B | |
| +8.28% | 297B | |
| -9.65% | 196B | |
| +6.72% | 199B | |
| -8.75% | 149B | |
| -5.21% | 146B |
- Stock Market
- Equities
- AZN Stock
- News AstraZeneca PLC
- AstraZeneca Sues Former Executive to Prevent Potential Therapy Data Leak to Rival GSK
